Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Br J Cancer. 2021 Oct;125(9):1185-1196. doi: 10.1038/s41416-021-01435-5. Epub 2021 Jul 14.
Although low risk localised prostate cancer has an excellent prognosis owing to effective treatments, such as surgery, radiation, cryosurgery and hormone therapy, metastatic prostate cancer remains incurable. Existing therapeutic regimens prolong life; however, they are beset by problems of resistance, resulting in poor outcomes. Treatment resistance arises primarily from tumour heterogeneity, altered genetic signatures and metabolic reprogramming, all of which enable the tumour to serially adapt to drugs during the course of treatment. In this review, we focus on alterations in the metabolism of prostate cancer, including genetic signatures and molecular pathways associated with metabolic reprogramming. Advances in our understanding of prostate cancer metabolism might help to explain many of the adaptive responses that are induced by therapy, which might, in turn, lead to the attainment of more durable therapeutic responses.
尽管由于有效的治疗方法，如手术、放疗、冷冻手术和激素治疗，低风险局限性前列腺癌具有极好的预后，但转移性前列腺癌仍然无法治愈。现有的治疗方案可以延长生命；然而，它们存在耐药的问题，导致预后不佳。治疗耐药性主要源于肿瘤异质性、遗传特征改变和代谢重编程，所有这些都使肿瘤在治疗过程中能够对药物进行连续适应。在这篇综述中，我们重点关注前列腺癌代谢的改变，包括与代谢重编程相关的遗传特征和分子途径。我们对前列腺癌代谢的理解的进展可能有助于解释许多由治疗引起的适应性反应，这反过来又可能导致获得更持久的治疗反应。
